ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0806

Coping with Recent-onset Rheumatoid Arthritis (RA): Validation of the Coping with Health Injuries and Problems (CHIP) Questionnaire in a Longitudinal Cohort

Zafer Alman1, Gilles Boire2, Nathalie Carrier3, Ariel Masetto2, Artur deBrum Fernandes4, Patrick Liang2, Patricia L Dobkin5, Allard-Chamard Hugues6 and Sophie Roux7, 1Cerrahpasa Faculty of Medicine, Istambul, Turkey, 2Universite de Sherbrooke, Sherbrooke, QC, Canada, 3CIUSSS de l'Estrie - CHUS, Sherbrooke, QC, Canada, 4Universite De Sherbrooke, Fleurimont, QC, Canada, 5McGill University, Montréal, QC, Canada, 6Universit de Sherbrooke, Sherbrooke, QC, Canada, 7Université de Sherbrooke, Sherbrooke, QC, Canada

Meeting: ACR Convergence 2021

Keywords: CHIP, Chronic disease, coping, rheumatoid arthritis, validation

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 7, 2021

Title: RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)

Session Type: Poster Session B

Session Time: 8:30AM-10:30AM

Background/Purpose: Receiving a Rheumatoid Arthritis (RA) diagnosis presents a significant health stressor. Given that little is known about how patients cope with it, we aimed to validate for the first time the Coping with Health Injuries and Problems (CHIP) questionnaire (Endler NS et al. Psychol Assessm 1998;10:195) in early RA.

Methods: Between August 2006 and October 2020, 483 consecutive patients who met the criteria for RA were enrolled at the Centre Hospitalier Universitaire de Sherbrooke (CHUS). At baseline and at each scheduled yearly study visit, patients self-administered the CHIP questionnaire. CHIP is comprised of 32 items, with 4 subscales: Distraction, Palliative, Instrumental, Emotional. Each subscale is the sum of 8 items with a score ranging from 8 to 40. CHIP’s validity was assessed for internal consistency with Cronbach’s alpha, for sensitivity to change with mixed linear model with repeated measures as well as for factor structure with factorial analysis and confirmatory analysis.

Results: A total of 420 patients were followed up to 5 years. The baseline mean (SD) of 4 subscales were 24.01 (6.46) for Distraction, 23.58 (6.07) for Palliative, 31.48 (5.35) for Instrumental and 25.10 (7.95) for Emotional. CHIP demonstrated good psychometric properties. Internal consistency (Cronbach’s alpha) varied between 0.736 and 0.857 (Table 1); deleting each element separately did not improve the coefficient suggesting that each was an important contributor to the overall score. CHIP was sensitive to change with significant decreases (estimated ± SE) until 5 years for Instrumental (-4.25 ± 0.36, p< 0.001), Emotional (-5.87 ± 0.44, p< 0.001), Palliative (-1.27 ± 0.35, p< 0.001) and a significant increase for Distraction (1.15 ± 0.40, p=0.04) (Figure). Factor analysis suggested that all items were better represented on 7 subscales rather than 4; the 7-dimension solution explained 56.5% (versus 37.8%) of the total variability. The first subscale was defined by all 8 Emotional items; the second by 6 of 8 items of Distraction; five of the Instrumental items were found on dimension 3, the 3 others (linked to treatment adherence) were on dimension 5; Palliative items were split into 3 subscales (4, 6 and 7) that we called comfort, rest and well-being (Table 2). Confirmatory analyses showed that 7 subscales may be slightly better than the original 4, although Cronbach's alphas of the new 7 subscales were not improved when compared to the original 4.

Conclusion: CHIP questionnaire describes patient’s individual coping styles when facing recent-onset RA. Due to the prospective nature of our cohort, we could validate the questionnaire. Factor analysis suggested that coping in early RA was better characterized using 7 rather than 4 subscales, but Cronbach’s alpha suggested that using the original tool might be as good, an observation that remains to be confirmed. Discussing a patient’s results for CHIP may enable a rheumatologist to understand patients’ perspectives and address their needs better, thereby strengthening their relationship. Results from CHIP may also be used as predictor of patients’ outcomes pointing towards interventions that may help those in need to deal with their illness better.

Table 1. Cronbach’s alpha for original subscales of the CHIP questionnaire

Figure 1. Evolution of CHIP subscales over the five years following RA onset

Table 2. Results of factorial analysis using the 32 items of the CHIP questionnaire


Disclosures: Z. Alman, None; G. Boire, Abbvie, 1, 6, 7, BMS, 6, 7, Janssen, 1, 5, 6, Eli Lilly, 1, 7, Amgen, 7, Novartis, 6, 7, Pfizer, 7, Sandoz, 6, 7, Viatris, 1, 6, Samsung Bioepis, 1; N. Carrier, None; A. Masetto, AbbVie, 2, 5, 6, BMS, 2, 5, 6, Novartis, 2, 5, 6, Pfizer, 2, 5, 6, Sanofi, 2, 5, 6, UCB, 2, 5, 6, Eli Lilly, 2, 5, 6, Janssen, 2, 5, 6, Amgen, 5, Merck, 5, Teva, 5; A. deBrum Fernandes, None; P. Liang, Janssen, 1, 5, 6, Hoffman-La Roche, 5, Novartis, 1, 6, Abbvie, 1, 6, BMS, 1, 6, Amgen, 1, 6, Merk, 1, 6; P. Dobkin, None; A. Hugues, Pfizer, 1, 6, Neomed, 7, Daiichi Sankyo, 7, Abbvie, 1, 6, Xencor, 7, Sanofi, 1, 6, Novartis, 1, 6, Amgen, 1, 6, Hoffmann-La Roche, 1, 6, Eli Lilly, 1, 6, Janssen, 1, 5, 6; S. Roux, Amgen, 6.

To cite this abstract in AMA style:

Alman Z, Boire G, Carrier N, Masetto A, deBrum Fernandes A, Liang P, Dobkin P, Hugues A, Roux S. Coping with Recent-onset Rheumatoid Arthritis (RA): Validation of the Coping with Health Injuries and Problems (CHIP) Questionnaire in a Longitudinal Cohort [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/coping-with-recent-onset-rheumatoid-arthritis-ra-validation-of-the-coping-with-health-injuries-and-problems-chip-questionnaire-in-a-longitudinal-cohort/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/coping-with-recent-onset-rheumatoid-arthritis-ra-validation-of-the-coping-with-health-injuries-and-problems-chip-questionnaire-in-a-longitudinal-cohort/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology